
    
      This study is the first in human trial of GC3106 and is designed as an adaptive Phase I/IIa
      to ensure participants protection. Part A is an open-label and single arm study in 9 healthy
      volunteers. Data and Safety Monitoring Board (DSMB) will review the solicited/unsolicited
      adverse events conditionally if any toxicity of Grade 3 or 4 has been reported during 7 days
      after vaccination from the first 9 healthy volunteers. Part B is a randomized (2:1),
      double-blind, active controlled study and a total of 75 volunteers will participate in this
      part. Adverse events assessment will be done according to the 'Toxicity Grading Scale for
      Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials'.
    
  